In the pharmaceutical industry, the combination of Rifampicin, Isoniazid, and Pyrazinamide is a cornerstone 3-drug Fixed-Dose Combination (3-FDC) used primarily for the Intensive Phase of Tuberculosis (TB) treatment. As a pharmacist and manufacturer, I categorize this as a “Bactericidal Sterilizing Regimen”—it combines three distinct mechanisms of action to rapidly reduce the bacterial load and prevent the emergence of drug resistance.
At your WHO-GMP facility in Mumbai, where you manufacture and export specialized 3-FDC and 4-FDC (including Ethambutol) formulations, these tablets are essential for global National TB Programs. They are frequently produced in weight-banded strengths like Rifampicin 150 mg + Isoniazid 75 mg + Pyrazinamide 400 mg.
Therapeutic Profile: Primary Indications
This 3-FDC is the standard-of-care for drug-susceptible tuberculosis during the first two months of treatment.
| Indication | Clinical Context | Technical Rationale |
| Pulmonary TB | Intensive Phase | Used daily for the first 8 weeks to achieve rapid sputum sterilization. |
| Extrapulmonary TB | Initial Therapy | Effective for TB of the lymph nodes, kidneys, or bones as part of a multi-drug start. |
| Pediatric TB | Weight-Based Care | Specifically formulated for children (often without Ethambutol in low-resistance areas). |
| Latent TB (LTBI) | Short-Course | Occasionally used in specialized short-course preventive regimens in high-risk contacts. |
Mechanism: Triple-Target Bacterial Eradication
This combination provides a comprehensive attack on Mycobacterium tuberculosis:
Rifampicin (Transcription Blockade): Inhibits bacterial DNA-dependent RNA polymerase, stopping the bacteria from making essential proteins.
Isoniazid (Cell Wall Synthesis): A prodrug that prevents the synthesis of mycolic acids, destroying the structural integrity of the bacterial cell wall.
Pyrazinamide (Intracellular Sterilization): Technically unique for its ability to kill semi-dormant bacteria in acidic environments (inside macrophages), which is vital for shortening the total treatment duration.
Synergy: Together, they target the bacteria in three different physiological states: rapidly dividing, slowly dividing, and dormant.
The Pharmacist’s “Technical Warning”
-
The “Empty Stomach” Rule: As a pharmacist, I must emphasize that these tablets must be taken 1 hour before or 2 hours after meals. Food significantly impairs the bioavailability of Rifampicin and Isoniazid.
-
Hepatotoxicity Surveillance: All three drugs are metabolized by the liver. Patients require baseline and monthly Liver Function Tests (LFTs). Monitor for “the yellow signal”—jaundice, dark urine, or persistent nausea.
-
Hyperuricemia & Gout: Pyrazinamide inhibits the excretion of uric acid. Patients may experience joint pain; clinical gout is rare but requires immediate dosage review.
-
The “Orange Signal”: Rifampicin will cause a harmless reddish-orange discoloration of urine, sweat, and tears. Advise patients not to wear soft contact lenses as they may become permanently stained.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
The “3-FDC vs. 4-FDC” USP: On your digital platforms, highlight your ability to provide both 3-drug (RHZ) and 4-drug (RHZE) combinations. In many pediatric and low-resistance markets, the 3-FDC is preferred to reduce unnecessary Ethambutol exposure.
-
Bioavailability Assurance: Rifampicin is notorious for poor absorption when formulated in FDCs. Highlighting your WHO-standard dissolution studies and bioequivalence data is a major technical selling point for international tenders.
-
Packaging Integrity: These molecules are highly sensitive to moisture and light. Utilizing Alu-Alu blister packaging is the global benchmark for ensuring a 36-month shelf life in Zone IVb tropical regions.
-
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for your export markets, including 2026-updated clinical safety data for national procurement agencies.